Aprea Therapeutics Secures $3.1 Million Private Placement to Advance Cancer-Targeting Drug Development
核心洞察
Aprea Therapeutics raised $3.1 million through a private placement priced at-the-market under Nasdaq rules, with participation from new and existing healthcare-focused investors.
The financing is expected to extend the company's cash runway into Q1 2027, providing funding for continued development of its cancer vulnerability-targeting approach.
Aprea's lead programs include APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development for solid tumor indications.
Aprea Therapeutics, a clinical-stage biopharmaceutical company developing innovative cancer treatments, announced it has secured $3.1 million in gross proceeds through a private placement with new and existing healthcare-focused investors. The financing is structured to extend the company's operational runway into the first quarter of 2027, positioning it for potential clinical program inflection points during that period.
The company entered into a securities purchase agreement to sell 2,623,023 shares of common stock (or pre-funded warrants in lieu thereof), together with warrants to purchase up to an aggregate 2,623,023 shares of common stock. The combined effective offering price for each share and accompanying warrant is $1.165, with the warrants carrying an exercise price of $1.04 per share.
Innovative Cancer Treatment Approach
Aprea is pioneering a novel approach to cancer treatment by exploiting vulnerabilities associated with cancer cell mutations. This strategy was developed to kill tumors while minimizing effects on normal, healthy cells, potentially decreasing the risk of toxicity frequently associated with chemotherapy and other conventional treatments.
The company's technology platform has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal, prostate, and breast cancers.
Lead Clinical Programs
Aprea's pipeline is anchored by two lead programs currently in clinical development for solid tumor indications. APR-1051 is an oral, small-molecule inhibitor of WEE1 kinase, while ATRN-119 represents a small molecule ATR inhibitor. Both compounds are designed to exploit specific vulnerabilities in cancer cells while preserving healthy tissue function.
Financial Structure and Timeline
The private placement is being conducted under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, with securities not registered under federal or state securities laws. Maxim Group LLC (搜索) is serving as the sole placement agent for the offering, which is expected to close on or about December 10, 2025, subject to customary closing conditions.
The warrants issued in the placement will be exercisable immediately upon issuance and will expire on the five-year anniversary of either the effectiveness date of the registration statement covering resale of the securities or the date the underlying shares become eligible for resale under Rule 144.
Aprea intends to use the net proceeds for general corporate purposes and research and development expenses. The company believes the aggregate net proceeds will provide sufficient funding through 2027 based on current projections, allowing continued advancement of its clinical programs during a period when potential inflection points are anticipated.